Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.56 NOK | -3.00% | +0.41% | -31.96% |
May. 14 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 172
Sales per Business
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Vaccines and Immunotherapies
100.0
%
| 69 | 100.0 % | 136 | 100.0 % | +97.76% |
Sales per region
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 69 | 100.0 % | 136 | 100.0 % | +97.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Chief Tech/Sci/R&D Officer | 50 | 21-05-31 | |
Chief Tech/Sci/R&D Officer | - | 17-07-31 | |
Siri Torhaug
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Mette Husbyn
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-30 |
Mona Welschof
CTO | Chief Tech/Sci/R&D Officer | - | 13-09-30 |
Louise Stubbe
LAW | General Counsel | - | 21-12-31 |
Peter Fatum
PRN | Corporate Officer/Principal | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - | |
Chairman | 69 | 21-12-21 | |
Director/Board Member | 56 | - | |
Birgitte Volck
BRD | Director/Board Member | 61 | 21-05-04 |
Director/Board Member | 52 | - | |
Anders Tuv
BRD | Director/Board Member | 46 | - |
Elaine Sullivan
BRD | Director/Board Member | 63 | 22-05-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 326,546,444 | 179,598,448 ( 55.00 %) | 0 | 55.00 % |
Company contact information
Nykode Therapeutics ASA
Oslo Science Park Gaustadalléen 21
0349, Oslo
+47 22 95 81 93
http://www.nykode.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.96% | 468M | |
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |
- Stock Market
- Equities
- VACC Stock
- Company Nykode Therapeutics